Cyclerion Therapeutics (NASDAQ:CYCN) Announces Quarterly Earnings Results, Beats Expectations By $6.69 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings data on Tuesday. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($7.10) by $6.69, FiscalAI reports. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%.

Cyclerion Therapeutics Stock Performance

Shares of NASDAQ:CYCN traded up $0.03 during midday trading on Tuesday, hitting $3.52. The company’s stock had a trading volume of 6,374 shares, compared to its average volume of 2,590,489. The business’s 50 day simple moving average is $3.37 and its 200 day simple moving average is $2.60. The company has a market cap of $16.47 million, a P/E ratio of -2.59 and a beta of 1.76. Cyclerion Therapeutics has a 12-month low of $1.03 and a 12-month high of $8.48.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cyclerion Therapeutics currently has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is owned by institutional investors and hedge funds.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.